At today’s meeting of the Health and Social Care Select Committee, we questioned representatives of pharmaceutical companies, campaigners and the National Institute for Health and Care Excellence (NICE) on the controversial decision not to make Enhertu, a targeted drug for HER-2 secondary breast cancer, available in England and Wales – although it is used in Scotland and many other European countries.

You can watch some of my questions to company representatives and NICE here or read the full transcript here.